Reliance Life Sciences (RLS), part of India’s largest conglomerate, is expected to start phase I clinical studies of its indigenous Covid-19 vaccine soon. The Subject Expert Committee (SEC), which advises the drug regulator on vaccines and new drugs, reviewed the company’s application and is learnt to have recommended it for approval on Thursday.

Leave a Reply

Your email address will not be published. Required fields are marked *